Chemotherapy for non-small cell lung cancer.
作者信息
Carbone D P, Minna J D
出版信息
BMJ. 1995 Oct 7;311(7010):889-90. doi: 10.1136/bmj.311.7010.889.
Abstract
摘要
相似文献
1
Chemotherapy for non-small cell lung cancer.非小细胞肺癌的化疗
BMJ. 1995 Oct 7;311(7010):889-90. doi: 10.1136/bmj.311.7010.889.
2
[Therapeutic management of non-small-cell lung carcinoma (NSCLC) of stage III A].[ⅢA期非小细胞肺癌（NSCLC）的治疗管理]
Rev Pneumol Clin. 2001 Nov;57(5 Pt 2):S29-32.
3
[Management of non-small-cell lung carcinoma (NSCLC) of stage III B].[ⅢB期非小细胞肺癌（NSCLC）的管理]
Rev Pneumol Clin. 2001 Nov;57(5 Pt 2):S33-6.
4
[Adjuvant treatment for early stages of non-small-cell lung carcinoma (NSCLC)].[非小细胞肺癌（NSCLC）早期的辅助治疗]
Rev Pneumol Clin. 2001 Nov;57(5 Pt 2):S25-8.
5
[Cancer of the lung. New perspectives in medical treatment].[肺癌。医学治疗的新视角]
Arch Monaldi Mal Torace. 1989 Jul-Dec;44(4-6):781-90.
6
[Neoadjuvant treatment for early stages of non-small-cell lung carcinoma (NSCLC)].[非小细胞肺癌（NSCLC）早期的新辅助治疗]
Rev Pneumol Clin. 2001 Nov;57(5 Pt 2):S22-4.
7
Combined radiation and chemotherapy for unresectable non-small cell lung carcinoma.不可切除非小细胞肺癌的联合放疗与化疗
Lung Cancer. 1994 Mar;10 Suppl 1:S19-23. doi: 10.1016/0169-5002(94)91663-2.
8
Adjuvant vs neoadjuvant chemotherapy in resectable NSCLC: is that the real question?可切除非小细胞肺癌的辅助化疗与新辅助化疗：这是真正的问题所在吗？
Oncology (Williston Park). 2009 May;23(6):534-6, 538.
9
Chemotherapy of non-small cell lung cancer.非小细胞肺癌的化疗
Br J Cancer. 1989 Jul;60(1):9-11. doi: 10.1038/bjc.1989.209.
10
Chemotherapy in lung cancer.肺癌的化疗
Postgrad Med J. 1989 May;65(763):291-8. doi: 10.1136/pgmj.65.763.291.
引用本文的文献
1
A pharmacogenetics study of platinum-based chemotherapy in lung cancer: polymorphism and its genetic interaction with are associated with response and survival.肺癌铂类化疗的药物遗传学研究：多态性及其与……的基因相互作用与疗效和生存相关。 （注：原文中“its genetic interaction with are associated with”部分“with”后缺少具体内容）
J Cancer. 2021 Jan 1;12(5):1270-1283. doi: 10.7150/jca.51621. eCollection 2021.
2
Genetic polymorphism of is associated with clinical outcomes of platinum-based chemotherapy in non-small-cell lung cancer patients through modulating microRNA-mediated regulation.通过调节微小RNA介导的调控，[具体基因名称]的基因多态性与非小细胞肺癌患者铂类化疗的临床结局相关。 （注：原文中“Genetic polymorphism of ”这里缺少具体基因名称）
Oncotarget. 2018 May 8;9(35):23860-23877. doi: 10.18632/oncotarget.24794.
3
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.直面房间里的大象——非小细胞肺癌的治疗耐药性，采用表观遗传疗法。
Oncotarget. 2016 Jun 28;7(26):40781-40791. doi: 10.18632/oncotarget.8205.
4
Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer.GADD45A、GADD45B和MAPK14的基因变异可预测中国非小细胞肺癌患者铂类化疗引起的毒性反应。
Oncotarget. 2016 May 3;7(18):25291-303. doi: 10.18632/oncotarget.8052.
5
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.在KRAS突变型和KRAS野生型晚期非小细胞肺癌中使用和不使用厄洛替尼的司美替尼。
Ann Oncol. 2016 Apr;27(4):693-9. doi: 10.1093/annonc/mdw008. Epub 2016 Jan 22.
6
Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.吉西他滨。对其在非小细胞肺癌和胰腺癌中的药理学及临床应用潜力的综述。
Drugs. 1997 Sep;54(3):447-72. doi: 10.2165/00003495-199754030-00009.
7
Chemotherapy in non-small cell lung cancer. It may not be ethical to ask patients to participate in future trials.非小细胞肺癌的化疗。要求患者参与未来的试验可能不符合伦理道德。
BMJ. 1996 Jan 27;312(7025):249. doi: 10.1136/bmj.312.7025.249a.
本文引用的文献
1
A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.一项在可切除的IIIA期非小细胞肺癌中比较围手术期化疗联合手术与单纯手术的随机试验。
J Natl Cancer Inst. 1994 May 4;86(9):673-80. doi: 10.1093/jnci/86.9.673.
2
Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.非小细胞肺癌细胞系的内在化学抗性与HER-2/neu基因表达相关，但与ras基因突变无关。
J Natl Cancer Inst. 1993 Jun 2;85(11):897-901. doi: 10.1093/jnci/85.11.897.
3
A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.一项比较术前化疗加手术与单纯手术治疗非小细胞肺癌患者的随机试验。
N Engl J Med. 1994 Jan 20;330(3):153-8. doi: 10.1056/NEJM199401203300301.
4
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.c-erbB-2表达与淋巴结阳性早期乳腺癌女性辅助治疗的反应
N Engl J Med. 1994 May 5;330(18):1260-6. doi: 10.1056/NEJM199405053301802.
5
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.辅助性环磷酰胺、甲氨蝶呤和氟尿嘧啶用于治疗淋巴结阳性乳腺癌：20年随访结果
N Engl J Med. 1995 Apr 6;332(14):901-6. doi: 10.1056/NEJM199504063321401.
6
Resistance to cisplatin: how to deal with the problem?对顺铂的耐药性：如何应对这一问题？
Eur J Cancer. 1990 Jan;26(1):1-3. doi: 10.1016/0277-5379(90)90247-q.
7
Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines.
J Natl Cancer Inst Monogr. 1992(13):191-6.
Zotero 插件